Last Update 13 Mar 26

Fair value Increased 7.90%

HSIC: Improving Dental Demand And New CEO Leadership Will Support Upside

The analyst price target for Henry Schein has been raised from $83.21 to $89.79, reflecting updated models that factor in Q4 results, initial FY26 guidance, and what analysts describe as better growth visibility and a more supportive demand backdrop.

Analyst Commentary

Across the Street, recent research points to a more constructive stance on Henry Schein following Q4 results and initial FY26 guidance, with several firms revising their models and resetting price targets.

Bullish analysts are generally responding to what they see as better growth visibility, signs of improved end market demand, and updated earnings frameworks that extend into the later years of management's outlook. At the same time, a group of more cautious voices is keeping ratings in the Neutral or Hold range, signaling ongoing questions around how much upside is already reflected in current valuations and how durable recent trends may be.

Bullish Takeaways

Bullish analysts point to Q4 results and initial FY26 guidance as stronger than their prior assumptions, which has led to multiple price target resets clustered in the high US$80s to low US$100s.
Several firms describe better growth visibility and a more supportive demand backdrop after updating models, with some specifically citing improving patient demand in dental as a constructive signal for future execution.
Some bullish analysts see room for earnings expansion in their updated frameworks, with at least one highlighting potential for double digit earnings growth starting in 2027, which they factor into higher valuation ranges.
Upgrades into Outperform or equivalent ratings suggest that, for these analysts, the recent setup looks improved relative to earlier expectations, with Q4 performance and guidance viewed as supportive of their revised targets.

Bearish Takeaways

Bearish analysts, or those holding Neutral, Hold or Market Perform ratings, are raising price targets but stopping short of outright bullish calls, which signals that they see a more balanced risk reward at current levels.
One research view characterizes Henry Schein's recent results as stable rather than thesis changing, implying that while execution is solid, it may not fully reset longer term concerns in their models.
Cautious views reflect questions around how much of the improving demand and organic growth is driven by underlying trends versus shorter term factors such as timing of promotions.
Neutral and Hold ratings alongside updated price targets, including those around US$84 to US$88, suggest that some analysts see limited upside to their fair value estimates without clearer evidence of sustained growth and margin traction.

What's in the News

Henry Schein issued earnings guidance for 2026, with total sales growth expected to be approximately 3% to 5% over 2025, giving investors a clearer view of management's baseline outlook for the year (Corporate Guidance).
The company completed a share repurchase tranche between September 28, 2025 and December 27, 2025, buying back 2,800,000 shares for US$200m, and finishing a broader program totaling 41,674,379 shares for US$2,970.31m that was first announced in December 2018 (Buyback Tranche Update).
For the fourth quarter ended December 27, 2025, Henry Schein reported a US$15m impairment charge on intangible assets, which will affect the period's reported earnings mix between cash and non cash items (Impairments/Write Offs).
Henry Schein entered an exclusive U.S. distribution agreement with CytoChip Inc. for the CitoCBC system, an FDA 510(k) cleared, CLIA waived cartridge based Complete Blood Count device that delivers lab quality results in about eight minutes in near patient settings, including physician offices, urgent care centers and certain small hospitals (Client Announcements).
The Board approved amended by laws on January 10, 2026 that, among other changes, remove the requirement to appoint a President and allow the CEO role to be separate from the President or Chairman roles. The company named Frederick M. Lowery as CEO effective March 2, 2026, with longtime CEO Stanley M. Bergman remaining as Chairman to support the leadership transition (Changes in Company Bylaws/Rules; Executive Changes).

Valuation Changes

Fair Value: updated from $83.21 to $89.79, a modest upward reset in the modeled target level.
Discount Rate: held steady at 6.98%, indicating no change in the assumed risk profile used in the models.
Revenue Growth: adjusted from 3.62% to 3.87%, reflecting a slightly higher projected revenue growth rate.
Net Profit Margin: moved from 4.08% to 4.03%, a small reduction in modeled profitability on future earnings.
Future P/E: increased from 16.87x to 17.54x, pointing to a somewhat higher valuation multiple in the updated framework.

0 views

Key Takeaways

Focus on high-margin segments, digital transformation, and operational efficiencies is expected to boost margins and earnings growth.
Demographic shifts and industry consolidation are likely to drive sustained demand and enhance customer loyalty in key markets.
Margin pressures from competitive pricing, staffing constraints, regulatory hurdles, and execution risks could limit revenue growth and profitability despite stabilization efforts in key business areas.

Catalysts

About Henry Schein

Provides health care products and services to office-based dental and medical practitioners, and alternate sites of care worldwide.What are the underlying business or industry changes driving this perspective?

The company is experiencing strong growth in high-margin businesses such as Specialty Products, Technology, and private-label offerings, and expects over 50% of non-GAAP operating income to come from these segments-supporting structurally higher gross margins and likely driving earnings expansion.
Investments in digital workflow, AI solutions, and integrated cloud-based practice management platforms are accelerating recurring SaaS revenues and client retention, positioning Henry Schein to benefit from the ongoing digital transformation of healthcare, which should support both revenue growth and improved margins.
Henry Schein is actively pursuing operational efficiencies-including $100M+ cost savings run-rate by end of 2025 and further value creation initiatives led by KKR's Capstone-which are expected to lower operating expenses and drive net margin improvement from 2026 onward.
Continued expansion of the company's Home Solutions platform to meet increased demand for at-home healthcare, coupled with robust demographic drivers from an aging global population, are anticipated to support sustained volume growth in core distribution and specialty lines, providing a foundation for long-term revenue growth.
Dental and medical practice consolidation is increasing client reliance on integrated supply, technology, and value-added service partners like Henry Schein, enhancing share gains and customer stickiness across both the U.S. and international markets-with positive implications for top-line growth and earnings stability.

Henry Schein Earnings and Revenue Growth

Henry Schein Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Henry Schein's revenue will grow by 4.0% annually over the next 3 years.
Analysts assume that profit margins will increase from 3.0% today to 4.3% in 3 years time.
Analysts expect earnings to reach $614.4 million (and earnings per share of $4.67) by about September 2028, up from $389.0 million today.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 16.1x on those 2028 earnings, down from 21.1x today. This future PE is lower than the current PE for the US Healthcare industry at 21.0x.
Analysts expect the number of shares outstanding to decline by 2.74% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.

Henry Schein Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Persistent competitive pricing pressures, especially in key categories like gloves (where pricing remains very competitive and still below previous year levels), could continue to weigh on distribution gross margins, reducing profitability and potentially hindering earnings growth even as volume stabilizes.
Flat to modest dental patient traffic and ongoing staffing shortages (notably in hygienists and office support) are constraining underlying volume growth in the core dental business globally, which limits organic revenue expansion and exposes results to macroeconomic or reimbursement shocks in key markets.
Greater customer price sensitivity due to tariffs and the potential for large DSO/group customers to actively RFP portions of their business places greater bargaining power with customers, risking margin compression and slower top-line growth if Henry Schein cannot fully offset price concessions with its owned brands or value-added services.
International expansion, while producing some bright spots, faces country-specific regulatory challenges (e.g. recent law changes in France), currency volatility, and localized competition, all of which could restrict anticipated revenue diversification and net earnings contribution from outside the U.S.
The multi-year leadership transition and implementation of cost-saving/value creation initiatives with KKR/consulting partners carry significant execution risk; delays, integration hurdles, or cultural disruption could impair near-term efficiency gains, and if technology or AI investments lag or under-deliver, Henry Schein could lose share to more innovative or nimble competitors, pressuring long-term earnings growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $73.231 for Henry Schein based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $83.0, and the most bearish reporting a price target of just $55.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $14.4 billion, earnings will come to $614.4 million, and it would be trading on a PE ratio of 16.1x, assuming you use a discount rate of 6.8%.
Given the current share price of $67.65, the analyst price target of $73.23 is 7.6% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Henry Schein?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

HSIC: Earnings Momentum From Automation And E-Commerce Will Shape Outlook